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Immunomodulatory antibodies that enhance the immune system to fight cancer are revolutionizing the treatment
of patients with an expanding variety of malignancies. There is a unique spectrum of side effects associated with
immunomodulatory antibodies, termed immune-related adverse events (irAEs), which include colitis and hepatitis
among others. The treatment of refractory or severe irAEs can occasionally require significant immunosuppression,
involving steroids or tumor necrosis factor-alpha antagonists, placing these patients at risk for infections. We present
the first reported case to our knowledge of an opportunistic infection in a patient treated with an immunomodulatory
antibody. As the use of immunomodulatory antibodies expands and more patients develop irAEs that require treatment
with immunosuppression, recognition of the potential for opportunistic infections in this emerging patient population will
be critical. Prospective trials are needed to define the optimal immunosuppressive management of irAEs and determine
whether prophylactic antiviral, antibacterial, or antifungal therapies are beneficial in this unique population.
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T-cell checkpoint blockade is one of the most active
areas of cancer research and has demonstrated dramatic
results in patients with a variety of cancers [1-5]. Ipili-
mumab, an antibody against cytotoxic T-lymphocyte-
associated antigen 4, was the first immunomodulatory
checkpoint inhibitor approved by the US Food and Drug
Administration for patients with advanced melanoma
[1]. Programmed cell death-1 (PD-1) receptor, another
immunologic checkpoint, has also shown great promise
as a therapeutic target in a variety of malignancies [4-6].
T-cell checkpoint blockade can result in side effects
called immune-related adverse events (irAEs), most com-
monly involving the skin (rash) and, particularly with
ipilimumab, gastrointestinal tract (diarrhea, hepatitis).
Refractory or severe irAEs often require treatment with
prolonged immunosuppression including high-dose ste-
roids and sometimes the addition of tumor necrosis
factor-alpha blockade or other immunosuppressants [7].
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mediated colitis requiring treatment with steroids and
infliximab, and later developed an opportunistic infection
with Aspergillus. This is the first case to be reported to
our knowledge that specifically highlights the potential
for developing opportunistic infections in this emerging
patient population.Case presentation
A 48-year-old Caucasian man was diagnosed with primary
cutaneous melanoma in 1991 when he was noted to have
a pigmented lesion on his posterior right neck. Subse-
quent biopsy showed Breslow depth 2 mm melanoma. No
information about the presence or absence of ulceration
was available. He underwent wide local excision with
pathology demonstrating no residual disease. A sentinel
lymph node biopsy was not pursued.
The patient remained free of disease for 20 years until
the age of 68 when he developed new hypertension,
prompting a renal ultrasound that showed normal kid-
neys. Two hepatic lesions were incidentally noted. A
subsequent positron emission tomography (PET) scan
demonstrated bilobar hepatic metastases and multiple
pulmonary metastases concerning for metastatic disease.This is an Open Access article distributed under the terms of the Creative
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firmed metastatic melanoma. Mass-spectrometry genotyp-
ing (Sequenom) revealed no known mutations that affect
the gene encoding serine-threonine protein kinase BRAF
(e.g., the BRAF V600E mutation).
Three weeks later, the patient began treatment with
ipilimumab (3 mg/kg). After three doses of ipilimumab
(approximately two months of therapy), he developed sig-
nificant diarrhea. Colonoscopy with biopsy showed active
colitis. He received two doses of infliximab (5 mg/kg,
separated by 9 days) and high-dose systemic corticosteroids
(methylprednisolone 2 mg/kg/day for one day, followed by
prednisone 1 mg/kg/day tapered over one month) with
ultimate resolution of his diarrhea.
A computerized tomography (CT) scan three months
after starting ipilimumab demonstrated response of pul-
monary and hepatic metastases. However, new bilateral
cavitary pulmonary consolidations were noted concerning
for fungal pneumonia (Figure 1a-b). At this time, the
patient had no cough, fever, shortness of breath, or other
pulmonary symptoms. Bronchoscopy was performed and
bronchoalveolar lavage revealed Aspergillus fumigatus
pneumonia with a lavage fluid also positive for galacto-
mannan. Voriconazole and liposomal amphotericin B
treatment for a 14-day course resulted in ultimate radio-
graphic improvement (Figure 1c). Although his responseFigure 1 Images and timeline of Aspergillus infection in patient treat
event. (a) Baseline chest CT scan prior to ipilimumab. (b) Three weeks afte
CT scans showed cavitary pulmonary consolidations (white arrow). Subsequ
pneumonia. (c) After a 14-day treatment with antifungals, repeat CT scan s
increased bilateral pleural effusions. (d) Timeline of described events (not tto ipilimumab lasted approximately six months, he later
had disease progression and unfortunately passed away
due to metastatic disease.
Conclusions
As the use of immunomodulatory antibodies that block
T-cell checkpoints expands, so too may the complications
associated with this treatment. The unique spectrum of
immune-mediated toxicities from these agents has been
well characterized and algorithms for suggested immuno-
suppression regimens have been developed. However, the
potential for opportunistic infections to arise as a result of
the immunosuppression necessary to treat an irAE has
not previously been highlighted. Though we have chosen
to describe this one illustrative case, we have observed
additional cases at our institution, including patients
with Fournier’s gangrene and cytomegalovirus viremia.
Clinicians across the spectrum of internal medicine must
have a high degree of suspicion for the development of
these rare infections as early recognition, diagnosis,
and treatment are essential to achieve favorable clinical
outcomes.
Consensus guidelines instruct clinicians on the prophy-
laxis and treatment of opportunistic infections arising in
patients following hematopoietic stem cell transplantation
[8]. As we learn more from patients treated with theseed with steroids for management of an immune-related adverse
r receiving high-dose immunosuppression for immune-related colitis,
ent bronchoalveolar lavage was consistent with Aspergillus fumigatus
howed radiographic improvement in cavitary consolidations, but
o scale).
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may be necessary to define the optimal management
strategies for irAEs while also minimizing infectious
complications in this unique patient population. Ultim-
ately, prospective trials may be needed to optimize the
management of irAEs, taking into account the associated
secondary infectious risks.
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